PartnershipsEvent: September 3, 2026
Migration Biotherapeutics Limited and National Physical Laboratory (NPL) have collaborated to develop a materials-based platform to treat lethal cancers including Glioblastoma.
Published
Signal category
Partnerships
Quote
“The collaboration between Migration Biotherapeutics Limited and National Physical Laboratory (NPL) has been pivotal to the incredible progress we've made in the last year”
— Migration Biotherapeutics Limited team
Company
Migration Biotherapeutics Limited
Trapping Cancer: Guiding Cells, Rapidly Transforming Health
- Industry
- Biotechnology Research
- Location
- Cardiff, GB
- Company size
- 4 employees
Our ALIGHT(TM) technology helps neurosurgeons who want to provide patients with a better outcome than at most 18 months survival current average. By counteracting the spread of tumour-maintaining cells which ‘hitch-hike’ rapidly through healthy tissue and by giving existing treatments a better chance to take on the cancer without trading off quality of life.
Founded 2020